切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2023, Vol. 17 ›› Issue (04) : 311 -315. doi: 10.3877/cma.j.issn.1674-0793.2023.04.017

综述

肥胖合并甲状腺癌相关机制的研究进展
李永浩, 高雪菲, 郭田田, 张进, 张彩针, 刘静()   
  1. 030000 太原,山西医科大学第一临床医学院
    030000 太原,山西医科大学第一医院甲状腺外科
  • 收稿日期:2022-12-21 出版日期:2023-08-01
  • 通信作者: 刘静
  • 基金资助:
    "四个一批"山西省医学科技创新团队建设项目(甲状腺癌临床诊治和基础研究创新团队)(2020TD16)

Advances in the research of mechanisms related to obesity combined with thyroid carcinoma

Yonghao Li, Xuefei Gao, Tiantian Guo, Jin Zhang, Caizhen Zhang, Jing Liu()   

  1. The First Clinical School of Shanxi Medical University, Taiyuan 030000, China
    Department of Thyroid Surgery, the First Hospital of Shanxi Medical University, Taiyuan 030000, China
  • Received:2022-12-21 Published:2023-08-01
  • Corresponding author: Jing Liu
引用本文:

李永浩, 高雪菲, 郭田田, 张进, 张彩针, 刘静. 肥胖合并甲状腺癌相关机制的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(04): 311-315.

Yonghao Li, Xuefei Gao, Tiantian Guo, Jin Zhang, Caizhen Zhang, Jing Liu. Advances in the research of mechanisms related to obesity combined with thyroid carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(04): 311-315.

近年来甲状腺癌的发病率逐年上升,而全球肥胖群体的数量也在同步增长。研究认为肥胖是甲状腺癌可能的风险因素,其中白细胞介素6、肿瘤坏死因子α、瘦素、脂联素、雌激素和促甲状腺激素均与甲状腺癌的发生发展有关,同时胰岛素抵抗和肠道菌群异常等代谢失调也以直接或间接作用促进甲状腺癌进展。尽管如此,肥胖合并甲状腺癌的相关致病机制尚不清楚。本综述通过阐述肥胖合并甲状腺癌的发生机制,以便为今后的基础和临床研究提供参考。

In recent years, the incidence of thyroid carcinoma has been increasing year by year, and the number of obese people worldwide is also increasing in parallel. Studies have identified obesity as a possible risk factor for thyroid cancer, in which interleukin 6, tumor necrosis factor alpha, leptin, adiponectin, estrogen and thyroid stimulating hormone are all associated with the development of thyroid carcinoma, while metabolic dysregulation such as insulin resistance and dysbiosis of intestinal flora also promote the development of thyroid carcinoma by indirect or direct effects. The progression of thyroid carcinoma is also facilitated by metabolic disorders such as insulin resistance and intestinal flora. Nevertheless, the pathogenic mechanisms associated with obesity combined with thyroid carcinoma are still unclear. In this review, we have searched the relevant literature in the past 5 years to describe the mechanisms of thyroid cancer in combination with obesity, in order to provide reference for future basic and clinical research.

[1]
Demetriou E, Fokou M, Frangos S, et al. Thyroid nodules and obesity[J]. Life (Basel). 2023, 13(6): 1292.
[2]
Kitahara CM, McCullough ML, Franceschi S, et al. Anthropometric factors and thyroid cancer risk by histological subtype: pooled analysis of 22 prospective studies[J]. Thyroid, 2016, 26(2): 306-318.
[3]
Fussey JM, Beaumont RN, Wood AR, et al. Does obesity cause thyroid cancer? A mendelian randomization study[J]. J Clin Endocrinol Metab, 2020, 105(7): e2398–2407.
[4]
Zhao S, Jia X, Fan X, et al. Association of obesity with the clinicopathological features of thyroid cancer in a large, operative population: A retrospective case-control study[J]. Medicine (Baltimore), 2019, 98(50): e18213.
[5]
Wang H, Wang P, Wu Y, et al. Correlation between obesity and clinicopathological characteristics in patients with papillary thyroid cancer: A study of 1 579 cases: A retrospective study[J]. PeerJ, 2020, 8: e9675.
[6]
Lee J, Lee CR, Ku CR, et al. Association between obesity and BRAFV600E mutation status in patients with papillary thyroid cancer[J]. Ann Surg Oncol, 2015, 22 Suppl 3: S683-S690.
[7]
Cnop M, Foufelle F, Velloso LA. Endoplasmic reticulum stress, obesity and diabetes[J]. Trends Mol Med, 2012, 18(1): 59–68.
[8]
Zheng R, Chen G, Li X, et al. Effect of IL-6 on proliferation of human thyroid anaplastic cancer stem cells[J]. Int J Clin Exp Pathol, 2019, 12(11): 3992-4001.
[9]
Lumachi F, Basso SM, Orlando R. Cytokines, thyroid diseases and thyroid cancer[J]. Cytokine, 2010, 50(3): 229-233.
[10]
Couto JP, Daly L, Almeida A, et al. STAT3 negatively regulates thyroid tumorigenesis[J]. Proc Natl Acad Sci USA, 2012, 109(35): E2361-E2370.
[11]
Sethi JK, Hotamisligil GS. Metabolic messengers: tumour necrosis factor[J]. Nat Metab, 2021, 3(10): 1302-1312.
[12]
Kobawala TP, Trivedi TI, Gajjar KK, et al. Significance of TNF-α and the adhesion molecules: L-Selectin and VCAM-1 in papillary thyroid carcinoma[J]. J Thyroid Res, 2016: 8143695.
[13]
Zhang N, Wang Q, Tian Y, et al. Expressions of IL-17 and TNF-α in patients with Hashimoto’s disease combined with thyroid cancer before and after surgery and their relationship with prognosis[J]. Clin Transl Oncol, 2020, 22(8): 1280-1287.
[14]
Dossus L, Franceschi S, Biessy C, et al. Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: the EPIC study[J]. Int J Cancer, 2018, 142(7): 1332-1342.
[15]
Gheorghe DC, Stanciu MM, Zamfirescu A, et al. TNF-α may exert different antitumor effects in response to radioactive iodine therapy in papillary thyroid cancer with/without autoimmune thyroiditis[J]. Cancers (Basel), 2021, 13(14): 3609.
[16]
Haase J, Weyer U, Immig K, et al. Local proliferation of macrophages in adipose tissue during obesity-induced inflammation[J]. Diabetologia, 2014, 57(3): 562–571.
[17]
Dogan R, Dogan EE, Guler EM, et al. Oxidative stress values of tumor core, edge, and healthy thyroid tissue in thyroid masses[J]. Eur Arch Otorhinolaryngol, 2021, 278(8): 2953–2960.
[18]
Xing M. Oxidative stress: A new risk factor for thyroid cancer[J]. Endocr Relat Cancer, 2012, 19(1): C7–C11.
[19]
Bétry C, Challan-Belval MA, Bernard A, et al. Increased TSH in obesity: evidence for a BMI-independent association with leptin[J]. Diabetes Metab, 2015, 41(3): 248-251.
[20]
Rehem RA, Elwafa WA, Elwafa RA, et al. Study of serum leptin in well-differentiated thyroid carcinoma: correlation with patient and tumor characteristics[J]. World J Surg, 2014, 38(10): 2621-2627.
[21]
Cheng SP, Chi CW, Tzen CY, et al. Clinicopathologic significance of leptin and leptin receptor expressions in papillary thyroid carcinoma[J]. Surgery, 2010, 147(6): 847-853.
[22]
Uddin S, Bavi P, Siraj AK, et al. Leptin-R and its association with PI3K/AKT signaling pathway in papillary thyroid carcinoma[J]. Endocr Relat Cancer, 2010, 17(1): 191-202.
[23]
Park JW, Han CR, Zhao L, et al. Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model[J]. Endocr Relat Cancer, 2016, 23(1): 53-63.
[24]
Kim WG, Cheng SY. Mechanisms linking obesity and thyroid cancer development and progression in mouse models[J]. Horm Cancer, 2018, 9(2): 108-116.
[25]
Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: A review of current evidence[J]. Endocr Rev, 2012, 33(4): 547-594.
[26]
Zhou Y, Yang Y, Zhou T, et al. Adiponectin and thyroid cancer: insight into the association between adiponectin and obesity[J]. Aging Dis, 2021, 12(2): 597-613.
[27]
Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, et al. Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies[J]. J Clin Endocrinol Metab, 2011, 96(12): E2023-E2028.
[28]
Kwon H, Park SE, Yun JS, et al. Serum Adiponectin and progranulin level in patients with benign thyroid nodule or papillary thyroid cancer[J]. Endocrinol Metab (Seoul), 2020, 35(2): 396-406.
[29]
Finck BN, Johnson RW. Tumor necrosis factor(TNF)-alpha induces leptin production through the p55 TNF receptor[J]. Am J Physiol Regul Integr Comp Physiol, 2000, 278(2): R537-R543.
[30]
He Y, Lu L, Wei X, et al. The multimerization and secretion of adiponectin are regulated by TNF-alpha[J]. Endocrine, 2016, 51(3): 456-468.
[31]
Liu J, Xu T, Ma L, et al. Signal pathway of estrogen and estrogen receptor in the development of thyroid cancer[J]. Front Oncol, 2021, 11: 593479.
[32]
Xing M. Molecular pathogenesis and mechanisms of thyroid cancer[J]. Nat Rev Cancer, 2013, 13(3): 184-199.
[33]
Xu N, Liu H, Wang Y, et al. Relationship between insulin resistance and thyroid cancer in Chinese euthyroid subjects without conditions affecting insulin resistance[J]. BMC Endocr Disord, 2022, 22(1): 58.
[34]
Vella V, Malaguarnera R. The emerging role of insulin receptor isoforms in thyroid cancer: clinical implications and new perspectives[J]. Int J Mol Sci, 2018, 19(12): 3814.
[35]
Manzella L, Massimino M, Stella S, et al. Activation of the IGF Axis in thyroid cancer: implications for tumorigenesis and treatment[J]. Int J Mol Sci, 2019, 20(13): 3258.
[36]
高琳, 王婧颖, 马素芳, 等. 肠道菌群与甲状腺相关疾病关系的研究进展[J]. 山西医科大学学报, 2023, 54(5): 707-710.
[37]
Watanabe H, Katsura T, Takahara M, et al. Plasma lipopolysaccharide binding protein level statistically mediates between body mass index and chronic microinflammation in Japanese patients with type 1 diabetes[J]. Diabetol Int, 2020, 11(3): 293-297.
[38]
Park S, Willingham MC, Qi J, et al. Metformin and JQ1 synergistically inhibit obesity-activated thyroid cancer[J]. Endocr Relat Cancer, 2018, 25(10): 865-877.
[1] 何金梅, 尹立雪, 谭静, 张文军, 王锐, 任梅, 廖明娇. 超声心肌做功技术对2型糖尿病患者潜在左心室心肌收缩功能损伤的评价[J]. 中华医学超声杂志(电子版), 2023, 20(10): 1029-1035.
[2] 刘婷婷, 林妍冰, 汪珊, 陈幕荣, 唐子鉴, 代东伶, 夏焙. 超声衰减参数成像评价儿童代谢相关脂肪性肝病的价值[J]. 中华医学超声杂志(电子版), 2023, 20(08): 787-794.
[3] 叶晓琳, 刘云飞, 庞明泉, 王海久, 任利, 侯立朝, 于文昊, 王志鑫, 樊海宁. 肝再生细胞来源及调控机制的研究进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 96-99.
[4] 纪凯伦, 郝少龙, 孙海涛, 韩威. 减重术后胆囊结石形成机制的新进展[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 100-103.
[5] 袁育韬, 邢金琳, 谢克飞, 殷凯. CT征象及BRAFV600E基因突变与甲状腺乳头状癌中央区淋巴结转移的相关性[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 611-614.
[6] 崔占斌, 乔军利, 张丽丽, 韩明强. 尿碘水平与甲状腺乳头状癌患者术后复发危险度分层的相关性[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 615-618.
[7] 陈垚, 徐伯群, 高志慧. 改良式中间上入路根治术治疗甲状腺癌的有效性安全性研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 619-622.
[8] 江振剑, 蒋明, 黄大莉. TK1、Ki67蛋白在分化型甲状腺癌组织中的表达及预后价值研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 623-626.
[9] 何吉鑫, 杨燕妮, 王继伟, 李建国, 谢铭. 肠道菌群及肠道代谢产物参与慢性便秘发生机制的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 495-499.
[10] 王旭, 师绍敏, 毛燕, 季上, 刘亚玲. 肝酶代谢与骨关节炎相关性的研究进展[J]. 中华老年骨科与康复电子杂志, 2023, 09(06): 379-384.
[11] 黄岩, 刘晓巍, 杨春玲, 兰烨. 急性胰腺炎合并糖尿病患者的临床特征及血糖代谢与病情严重度的相关性[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 439-442.
[12] 王磊, 李梦, 孙文利, 刘瑞, 王红春, 卢光泽, 赵颖, 郭进艳, 刘红星. 液相色谱质谱法对急性白血病患者血浆代谢组学的特征分析[J]. 中华临床医师杂志(电子版), 2023, 17(08): 850-857.
[13] 李田, 徐洪, 刘和亮. 尘肺病的相关研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(08): 900-905.
[14] 张大涯, 陈世锔, 陈润祥, 张晓冬, 李达, 白飞虎. 肠道微生物群对代谢相关脂肪性肝病发展的影响[J]. 中华临床医师杂志(电子版), 2023, 17(07): 828-833.
[15] 周加军, 余永武, 周涵, 刘勇, 张凌. 甲状旁腺切除对继发性甲状旁腺功能亢进患者骨密度及骨代谢的影响[J]. 中华临床医师杂志(电子版), 2023, 17(06): 706-710.
阅读次数
全文


摘要